Intas
-
Intas Biopharmaceuticals Wins Award for Quality Excellence in India
Intas Biopharmaceuticals has received Gold Award for Quality Excellence in the category of Formulations Unit. The award was conferred by Indian Drug Manufacturer’s Association (IDMA). The awards were presented by B S Jharwar, chairman, National…
Intas | 05 February 2010
-
Intas Biopharma to Market Drug for Multiple Myeloma
India-based oncology drug marketing company, Intas Biopharmaceuticals, has launched Bortezomib injection, under the brand name Borviz, in the Indian market. The injection offers treatment for Multiple Myeloma, the second-most common cancer of plasma …
Intas | 22 May 2009
-
Intas Biopharma to Market Pemetrexed in India
Intas Biopharmaceuticals is launching Pemetrexed under the brand name Pemmet, in India. The drug is used to treat non-small cell lung cancer (NSCLC), a common type of lung cancer caused primarily from smoking and Mesothelioma, a cancer caused by Asb…
Intas | 01 May 2009
-
India’s Intas Plans Filgrastim Launch in North America, Europe
Intas Biopharmaceuticals (IBPL) has signed an agreement with Canada–based Apotex for co-development and supply of its Filgrastim brand, Neukine in the US and Canada. European pharmaceutical major Kwizda Pharma, which is working with IBPL to dev…
Intas | 01 June 2008
-
Intas Biopharma Launches New Sales Divisions in India
Intas Biopharmaceuticals Limited (IBPL) announces formation of three new sales divisions, namely – TRACK, AQUA and RELAY to focus on the company’s product basket. The company’s newly formed divisions will take care of sales & marketing of b…
Intas | 20 March 2008
